• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Tuesday, July 14, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Biology

Standard fetal growth charts frequently miss identifying at-risk babies

Bioengineer by Bioengineer
July 9, 2026
in Biology
Reading Time: 2 mins read
0
Standard fetal growth charts frequently miss identifying at-risk babies
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Current fetal growth charts employed across England’s National Health Service (NHS) to monitor prenatal development may be misclassifying significant numbers of babies as either too small or too large. This discrepancy, revealed by a comprehensive study analyzing over 3.2 million births, highlights profound implications for perinatal care, including missed detection of growth restrictions associated with stillbirth and unnecessary medical interventions.

Fetal growth restriction, characterized by slower-than-expected intrauterine growth, is a critical predictor of adverse pregnancy outcomes. Detecting this condition prenatally is essential to improve neonatal safety and reduce avoidable perinatal deaths. However, the standard ‘one-size-fits-all’ growth charts currently implemented across NHS hospitals lack adjustment for maternal factors influencing fetal growth, such as maternal weight, ethnicity, and other physiological characteristics.

The study led by researchers at the Perinatal Institute in Birmingham compared seven widely used fetal growth standards, including Hadlock, Intergrowth-21st, World Health Organisation (WHO), Fetal Medicine Foundation (FMF), and the customised GROW charts. Unlike the universal charts, which use fixed references derived mostly from international populations, GROW employs a customizable algorithm, adapting fetal growth expectations based on individual maternal parameters.

Results underscored stark variability: rates of babies classified as small for gestational age (below the 10th centile) at term fluctuated considerably from 4.8% using Intergrowth charts to 17.2% with WHO and FMF charts, while GROW charts reported an intermediate rate of 12.3%. Moreover, unadjusted charts revealed inconsistent identification rates across different NHS regions reflecting local demographic differences, a variability not seen in customised assessments.

Importantly, the researchers utilized birthweight data for the analysis, acknowledging that ultrasound-estimated fetal weights might offer different insights but noting that birthweight metrics allowed inclusion of the entire cohort regardless of prenatal scan availability. The observational nature of the study provides strong epidemiological evidence but calls for further prospective validation.

These findings advocate urgent NHS-wide standardisation towards customised fetal growth assessment tools to enhance detection accuracy, improve clinical decision-making, and reduce avoidable fetal mortality. The study also calls for establishing real-time national oversight mechanisms to monitor chart performance, ensuring consistent quality and safety in maternity care.

The misapplication of non-personalised growth charts risks both false reassurance and overdiagnosis, potentially compromising maternal and fetal outcomes. This large-scale population study amplifies the pressing need for tailored clinical protocols that harmonize with diverse patient populations across the NHS.

As the NHS seeks to reduce perinatal mortality and improve antenatal care safety, adopting customised growth models may represent a critical evolution in fetal surveillance, aligning care with individual biological variance and scientific precision.

Subject of Research: People
Article Title: Designation of small for gestational age according to seven fetal growth charts in England’s National Health Service: population based cohort study of 3.2 million births
News Publication Date: 8-Jul-2026
Web References: http://dx.doi.org/10.1136/bmj-2026-433307
Keywords: Fetal growth charts, customized growth standards, fetal growth restriction, stillbirth risk, NHS maternity care, perinatal mortality, epidemiology

Tags: comparison of fetal growth standardscustomized versus universal growth chartsearly detection of growth abnormalitiesfetal growth restriction detectionimpact of maternal factors on fetal developmentimplications of fetal growth misclassificationmaternal ethnicity and weight influenceneonatal risk assessmentNHS fetal monitoring practicesperinatal care improvementspersonalized fetal growth chartspreventing stillbirth through accurate growth assessment

Share12Tweet7Share2ShareShareShare1

Related Posts

Uncanny Valley Effect Detected in Macaques Using 3D Animated Monkey Avatars

Uncanny Valley Effect Detected in Macaques Using 3D Animated Monkey Avatars

July 14, 2026
Aging Cells Revert to Stem Cells as Self-Repair Mimics

Aging Cells Revert to Stem Cells as Self-Repair Mimics

July 14, 2026

Study Finds Honey Bees’ Smell Senses Shift from Larvae to Adults

July 14, 2026

Genomic data reveal widespread hybridization and invasion history of saltcedar

July 14, 2026

POPULAR NEWS

  • New Drug Candidate Developed at McMaster Shows Potential for Treating Brain Cancer

    58 shares
    Share 23 Tweet 15
  • Detection of EDCs in Breast Milk and Infant Urine Up to Six Months Highlights Early Exposure Risks

    77 shares
    Share 31 Tweet 19
  • Experimental Therapy Simultaneously Destroys Prostate Tumor Cells and Reactivates Antitumor Immunity

    46 shares
    Share 18 Tweet 12
  • 高齢者の骨粗鬆症治療の持続性比較

    51 shares
    Share 20 Tweet 13

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

RASopathy Subtype Shapes Early Hypertrophic Cardiomyopathy Course, Study Finds

Informal Dementia Caregivers as Hidden Second Patients: Stress, Resilience, Burden

UniFFBench Benchmarks Universal Machine Learning Force Fields Using Experimental Data

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 85 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.